Sabby Volatility Fund Discloses 220,663 Scinai Immunotherapeutics ADSs
Ticker: SCNI · Form: SC 13G/A · Filed: Jan 2, 2024 · CIK: 1611747
| Field | Detail |
|---|---|
| Company | Scinai Immunotherapeutics Ltd. (SCNI) |
| Form Type | SC 13G/A |
| Filed Date | Jan 2, 2024 |
| Risk Level | low |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, amendment, beneficial-ownership
TL;DR
**Sabby Volatility Fund holds 220,663 Scinai Immunotherapeutics ADSs as of Dec 31, 2023.**
AI Summary
Sabby Volatility Warrant Master Fund, Ltd., a Cayman Islands-based entity, filed an amended SC 13G/A on January 2, 2024, disclosing its beneficial ownership in Scinai Immunotherapeutics Ltd. (formerly BiondVax Pharmaceuticals Ltd.). As of December 31, 2023, Sabby Volatility Warrant Master Fund, Ltd. reported shared voting power over 220,663 American Depositary Shares (ADSs) of Scinai Immunotherapeutics. This filing indicates a significant institutional investor's position in the company, which could influence stock perception and trading activity.
Why It Matters
This filing shows a notable institutional investor, Sabby Volatility Warrant Master Fund, Ltd., holds a significant stake in Scinai Immunotherapeutics, which can signal confidence or potential future trading activity to other investors.
Risk Assessment
Risk Level: low — This filing is a routine disclosure of beneficial ownership and does not inherently indicate a high level of risk.
Analyst Insight
Investors should note that a significant institutional investor holds a stake in Scinai Immunotherapeutics, which could be a factor in future stock performance. Monitoring subsequent filings from Sabby Volatility Warrant Master Fund, Ltd. would provide further insight into their investment strategy.
Key Numbers
- 220,663 — Shared Voting Power (Number of ADSs beneficially owned by Sabby Volatility Warrant Master Fund, Ltd. with shared voting power as of December 31, 2023.)
- 09073Q105 — CUSIP Number (Unique identification number for Scinai Immunotherapeutics Ltd. ADSs.)
- December 31, 2023 — Date of Event (The date as of which the beneficial ownership was reported.)
Key Players & Entities
- Sabby Volatility Warrant Master Fund, Ltd. (company) — reporting person and beneficial owner
- Scinai Immunotherapeutics Ltd. (company) — issuer of the securities
- BiondVax Pharmaceuticals Ltd. (company) — former name of the issuer
- Cayman Islands (company) — place of organization for Sabby Volatility Warrant Master Fund, Ltd.
- Sabby Management, LLC (company) — entity that filed on behalf of the reporting person
Forward-Looking Statements
- Sabby Volatility Warrant Master Fund, Ltd. will maintain a significant stake in Scinai Immunotherapeutics Ltd. in the near term. (Sabby Volatility Warrant Master Fund, Ltd.) — medium confidence, target: Q2 2024
FAQ
What is the primary purpose of this SC 13G/A filing?
The primary purpose of this SC 13G/A filing is for Sabby Volatility Warrant Master Fund, Ltd. to amend its previous Schedule 13G filing and disclose its beneficial ownership of American Depositary Shares (ADSs) in Scinai Immunotherapeutics Ltd. as of December 31, 2023.
Which entity is reporting beneficial ownership in Scinai Immunotherapeutics Ltd.?
Sabby Volatility Warrant Master Fund, Ltd., organized in the Cayman Islands, is the entity reporting beneficial ownership in Scinai Immunotherapeutics Ltd.
How many shares does the reporting person have sole voting power over?
The reporting person, Sabby Volatility Warrant Master Fund, Ltd., has sole voting power over 0 shares, as indicated in item 5 of the filing.
What was the former name of Scinai Immunotherapeutics Ltd.?
The former name of Scinai Immunotherapeutics Ltd. was BiondVax Pharmaceuticals Ltd., as stated in the filing under 'Name of Issuer' and 'FORMER COMPANY'.
Under which rule was this Schedule 13G filed?
This Schedule 13G was filed under Rule 13d-1(c), as indicated by the 'X' next to 'Rule 13d-1(c)' in the filing.
Filing Details
This Form SC 13G/A (Form SC 13G/A) was filed with the SEC on January 2, 2024 regarding Scinai Immunotherapeutics Ltd. (SCNI).